Lilly’s oral GLP-1 drug Orforglipron outperforms Semaglutide in phase 3 diabetes trial

Based on the cumulative data from ACHIEVE-1 through ACHIEVE-5, Lilly plans to submit orforglipron for FDA approval for the treatment of type 2 diabetes by the end of the second quarter

Novo Nordisk’s CagriSema delivers strong Phase 3 results across REIMAGINE diabetes trials

Scientists develop rapid nanosensor to detect gut health biomarker for IBD and diabetes

Novel fluorescent nanosensor enables real-time detection of indole-3-propionic acid (IPA), paving the way for faster gut health screening, point-of-care diagnostics, and wearable monitoring devices

India unveils first-ever national framework to tackle childhood diabetes

New policy aims to standardise screening, diagnosis and lifelong care for children with diabetes across India’s public health system

BPL Medical launches Blood Glucose Meter 582 for faster, easier diabetes monitoring

New home-use glucometer delivers results in under 10 seconds with simplified testing, large memory storage, and user-friendly design

Novo Nordisk posts strong late-stage results for oral diabetes pill in children and teens

The study evaluated oral semaglutide in young patients with type 2 diabetes and found it delivered a superior reduction in HbA1c

DKSH and Sanofi join forces to expand access to cardio & diabetes treatments in Southeast Asia

The aim is to bolster healthcare delivery in a region increasingly burdened by chronic disease

Lupin scores major US breakthrough with FDA nod for key diabetes drug

The Abbreviated New Drug Application with FDA covers multiple strengths of Dapagliflozin and Metformin Hydrochloride Extended-Release Tablets

The Semaglutide Surge: How a diabetes therapy sparked India’s weight loss wave

As demand for GLP-1 therapies explodes, India’s drug regulator moves to curb advertising amid rising concerns over misuse, access, and long-term impact

AstraZeneca, Roche-backed study supports risk-based HF screening in diabetes

Researchers say simple blood-test and echocardiography pathway could reshape diabetes-related cardiovascular care